# Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Source: https://onco.cc/trials/nct06533579/  
OnCo record `nct06533579` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Dose Level 1, VNX-101 in acute lymphoblastic leukaemia, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia, non-Hodgkin lymphoma, follicular lymphoma and mantle cell lymphoma, run by Vironexis Biotherapeutics Inc., now recruiting.

## Summary

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) is a phase 1/2 interventional study registered as NCT06533579 by Vironexis Biotherapeutics Inc., with 32 participants planned, started 2025-05-30 and due to reach its primary completion in 2027-06. Interventions recorded: Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 and Dose Level 4, VNX-101.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06533579
- Phase: 1/2
- Setting: A Phase 1/2 Safety, Dose-finding, and Pharmacokinetics Study of VNX-101 Gene Therapy in Patients With Relapsed or Refractory CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Sponsor: Vironexis Biotherapeutics Inc.
- Enrolled: 32

## Sources

- ClinicalTrials.gov NCT06533579: https://clinicaltrials.gov/study/NCT06533579

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/nct06533579.json